Tags

Type your tag names separated by a space and hit enter

Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial.
Clin Exp Allergy. 2010 May; 40(5):795-804.CE

Abstract

BACKGROUND

Clinical trials investigating the therapeutic effect of probiotics on atopic dermatitis (AD) show inconsistent results. Better results can possibly be achieved by combining probiotics with prebiotics, i.e. synbiotics.

OBJECTIVE

To investigate the therapeutic effect of a synbiotic mixture on the severity of AD in infants.

METHODS

In a double-blind, placebo-controlled multi-centre trial, 90 infants with AD [SCORing Atopic Dermatitis (SCORAD) score > or =15], aged < 7 months and exclusively formula fed, were randomly assigned to receive either an extensively hydrolysed formula with Bifidobacterium breve M-16V and a galacto-/fructooligosaccharide mixture (Immunofortis), or the same formula without synbiotics for 12 weeks. The primary outcome was severity of AD, assessed using the SCORAD index. A secondary outcome measure was intestinal microbiota composition.

RESULTS

There was no difference in SCORAD score improvement between the synbiotic and the placebo group. The synbiotic group did have a significantly higher percentage of bifidobacteria (54.7% vs. 30.1%, P<0.001) and significantly lower percentages of Clostridium lituseburense/Clostridium histolyticum (0.5 vs. 1.8, P=0.02) and Eubacterium rectale/Clostridium coccoides (7.5 vs. 38.1, P<0.001) after intervention than the placebo group. In the subgroup of infants with IgE-associated AD (n=48), SCORAD score improvement was significantly greater in the synbiotic than in the placebo group at week 12 (-18.1 vs. -13.5 points, P=0.04).

CONCLUSIONS

This synbiotic mixture does not have a beneficial effect on AD severity in infants, although it does successfully modulate their intestinal microbiota. Further randomized-controlled trials should explore a possible beneficial effect in IgE-associated AD.

Authors+Show Affiliations

Department of Pediatric Respiratory Medicine and Allergy, Emma Children's Hospital, Amsterdam, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20184604

Citation

van der Aa, L B., et al. "Effect of a New Synbiotic Mixture On Atopic Dermatitis in Infants: a Randomized-controlled Trial." Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 40, no. 5, 2010, pp. 795-804.
van der Aa LB, Heymans HS, van Aalderen WM, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. Clin Exp Allergy. 2010;40(5):795-804.
van der Aa, L. B., Heymans, H. S., van Aalderen, W. M., Sillevis Smitt, J. H., Knol, J., Ben Amor, K., Goossens, D. A., & Sprikkelman, A. B. (2010). Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 40(5), 795-804. https://doi.org/10.1111/j.1365-2222.2010.03465.x
van der Aa LB, et al. Effect of a New Synbiotic Mixture On Atopic Dermatitis in Infants: a Randomized-controlled Trial. Clin Exp Allergy. 2010;40(5):795-804. PubMed PMID: 20184604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. AU - van der Aa,L B, AU - Heymans,H S, AU - van Aalderen,W M, AU - Sillevis Smitt,J H, AU - Knol,J, AU - Ben Amor,K, AU - Goossens,D A, AU - Sprikkelman,A B, AU - ,, Y1 - 2010/02/22/ PY - 2010/2/27/entrez PY - 2010/2/27/pubmed PY - 2010/9/21/medline SP - 795 EP - 804 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin. Exp. Allergy VL - 40 IS - 5 N2 - BACKGROUND: Clinical trials investigating the therapeutic effect of probiotics on atopic dermatitis (AD) show inconsistent results. Better results can possibly be achieved by combining probiotics with prebiotics, i.e. synbiotics. OBJECTIVE: To investigate the therapeutic effect of a synbiotic mixture on the severity of AD in infants. METHODS: In a double-blind, placebo-controlled multi-centre trial, 90 infants with AD [SCORing Atopic Dermatitis (SCORAD) score > or =15], aged < 7 months and exclusively formula fed, were randomly assigned to receive either an extensively hydrolysed formula with Bifidobacterium breve M-16V and a galacto-/fructooligosaccharide mixture (Immunofortis), or the same formula without synbiotics for 12 weeks. The primary outcome was severity of AD, assessed using the SCORAD index. A secondary outcome measure was intestinal microbiota composition. RESULTS: There was no difference in SCORAD score improvement between the synbiotic and the placebo group. The synbiotic group did have a significantly higher percentage of bifidobacteria (54.7% vs. 30.1%, P<0.001) and significantly lower percentages of Clostridium lituseburense/Clostridium histolyticum (0.5 vs. 1.8, P=0.02) and Eubacterium rectale/Clostridium coccoides (7.5 vs. 38.1, P<0.001) after intervention than the placebo group. In the subgroup of infants with IgE-associated AD (n=48), SCORAD score improvement was significantly greater in the synbiotic than in the placebo group at week 12 (-18.1 vs. -13.5 points, P=0.04). CONCLUSIONS: This synbiotic mixture does not have a beneficial effect on AD severity in infants, although it does successfully modulate their intestinal microbiota. Further randomized-controlled trials should explore a possible beneficial effect in IgE-associated AD. SN - 1365-2222 UR - https://www.unboundmedicine.com/medline/citation/20184604/Effect_of_a_new_synbiotic_mixture_on_atopic_dermatitis_in_infants:_a_randomized_controlled_trial_ L2 - https://doi.org/10.1111/j.1365-2222.2010.03465.x DB - PRIME DP - Unbound Medicine ER -